
## Global survey study of awareness, care and treatment of adolescents living with obesity, their caregivers and healthcare professionals: ACTION Teens

Jason C.G. Halford¹; Louise Baur²; Abdullah Bereket³; Bassam Bin-Abbas⁴; Walter Chen⁵; Fernando Fernandez-Aranda⁶; Nayely Garibay Nieto⁷; Juan Pedro López Siguero<sup>8</sup>; Claudio Maffeis<sup>9</sup>; Vicki Mooney<sup>10</sup>; Cynthia Karenina Osorto<sup>11</sup>; Ricardo Reynoso<sup>12</sup>; Young-Jun Rhie<sup>13</sup>; Martin Toro Ramos<sup>14</sup>



# ACTION Teens is the largest study of adolescents living with obesity and is unique in surveying three groups of stakeholders



## Background

- Obesity that is present in adolescence is likely to persist into adulthood,<sup>1</sup> and has a more severe lifelong impact than adultonset obesity.<sup>2,3</sup>
- Early intervention is indicated in children and adolescents living with obesity (ALwO), as it predicts better long-term reduction in body mass index (BMI).<sup>4</sup>
- Even modest BMI reductions are associated with improvement in cardiometabolic risk.<sup>5</sup>
- ACTION Teens aims to improve obesity management and treatment for ALwO by:
- Generating evidence to drive awareness of the needs of ALwO and caregivers
- Identifying areas of misalignment among ALwO, caregivers and healthcare providers (HCPs).

## Methods

- ACTION Teens is a landmark crosssectional, quantitative survey-based study.
- Primary outcome: describe awareness, perceptions and behaviours related to obesity and its management among ALwO, their caregivers and HCPs.
- Survey materials were designed under the guidance of an international steering committee (SC) consisting of HCPs and subject matter experts. Separate but overlapping surveys were developed for each sample group.
- Question domains are shown in Figure 1.

Figure 1: Survey domains



#### **Participants**

In each participating country (Figure 2), ALwO caregivers were recruited from a general population sample (stratified to match local demographic targets for adults); permission was sought for the relevant ALwO to be involved. HCPs were recruited from online physician panels. Key inclusion criteria are shown in Table 1.

### Data collection

 Cross-sectional data were obtained from online surveys, although in-person administration was permitted in Saudi Arabia, Taiwan and Turkey.

**Table 1:** Key inclusion criteria

ALWO	Caregivers of ALwO	HCPs
<ul> <li>Aged ≥12 to &lt;18 years</li> <li>Obesity according to BMI ≥95th percentile for age and sex, per locally appropriate definitions</li> </ul>	<ul> <li>Parent or legal guardian of an ALwO who lives in the same household ≥50% of the time</li> <li>Involved in the ALwO's healthcare decisions</li> </ul>	<ul> <li>Primary care physicians, paediatricians or specialists who see ≥10 ALwO in a typical month</li> <li>Spend ≥50% of time in direct patient care</li> </ul>

## Figure 2: Anticipated number of respondents

## Global study surveying ~14,600 people



#### Data analysis

- Sample sizes were selected to reflect local ALwO populations and to balance recruitment feasibility and statistical power, with the intention of performing local sub-analyses.
- All respondents who completed the survey will be included in the full analysis set.
- Statistical analyses will include:
- Descriptive statistics for all outcome measures across the total population for each country and for data subsets (e.g. group age, sex and region)
- Classical tests of hypotheses to identify differences in responses between data
- Linear regression and Pearson correlation coefficients to model relationships between outcomes of interest for key data subsets (e.g. ALwO age and sex).
- Caregivers of ALwO data will be weighted on key local demographic targets (based on government or peer-reviewed data) to reflect local adult populations.
- It would not have been possible to directly assess the impact of pubertal stage on outcomes without including potentially culturally inappropriate questions. Thus, a proxy of age subgroups was considered appropriate by the SC.

## Strengths of study design

- Analysis of three key stakeholders ALwO, their caregivers and HCPs – across 10 countries
- Use of locally appropriate age-specific definitions of obesity
- Stratified sampling and demographic weighting of ALwO caregivers to mitigate selection bias and for generalisability
- 'Matched pairs' of ALwO and caregivers were maximised by seeking permission for the relevant ALwO to be involved

## **Data dissemination**

- Results will be reported in 2022, with overall data published before local data.
- If variables of interest are identified, additional sub-analyses may be considered (under SC guidance).

## Conclusions

- ACTION Teens, a landmark study and the largest of its kind, will provide critical global insights to improve awareness of management, treatment and support for ALwO.
- Insights will be used to guide collaborative action to improve care, education and support for ALwO and their caregivers, and create a communication platform to help change how ALwO, caregivers and HCPs manage, treat and support obesity.
- Due to the cross-sectional design, it will not be possible to determine causal relationships, but data may help to generate hypotheses for future studies.

#### References:

(1) Simmonds M, et al. Obes Rev 2016:17;95–107; (2) Coutinho W, et al. Obes Rev 2020:21;e13115 (AD10-02); (**3**) Twig G, et al. N Engl J Med 2016:374;2430–40; (**4**) Reinehr T, et al. Am J Clin Nutr 2010:91;1165–71; (5) Kolsgaard MLP, et al. BMC Pediatr 2011:11;47.

¹School of Psychology, University of Leeds, Leeds, UK; ²Children's Hospital Westmead Clinical School, The University of Sydney, New South Wales, Australia; ³Department of Pediatric Endocrinology and Diabetes, Marmara University of Sydney, New South Wales, Australia; ³Department of Pediatric Endocrinology and Diabetes, Marmara University of Sydney, New South Wales, Australia; ³Department of Pediatric Endocrinology and Diabetes, Marmara University of Sydney, New South Wales, Australia; ³Department of Pediatric Endocrinology and Diabetes, Marmara University of Sydney, New South Wales, Australia; ³Department of Pediatric Endocrinology and Diabetes, Marmara University of Sydney, New South Wales, Australia; ³Department of Pediatric Endocrinology and Diabetes, Marmara University of Sydney, New South Wales, Australia; ³Department of Pediatric Endocrinology and Diabetes, Marmara University of Sydney, New South Wales, Australia; ³Department of Pediatric Endocrinology and Diabetes, Marmara University of Sydney, New South Wales, Australia; ³Department of Pediatric Endocrinology and Diabetes, Marmara University of Sydney, New South Wales, Australia; ³Department of Pediatric Endocrinology and Diabetes, Marmara University of Sydney, New South Wales, New South Center, Riyadh, Saudi Arabia; 5 Children's Hospital, China Medical University, Taichung, Taiwan; 6 Department of Psychiatry, University Hospital of Bellvitge-IDIBELL and CIBEROBN, Barcelona, Spain; 7 Pediatric Obesity Clinic and Wellness Unit, Hospital General de México "Dr. Eduardo Liceaga", Mexico City, Mexico; 8 Pediatric Endocrinology Unit, 10 Company Regional University Hospital, Málaga, Spain; Department of Surgery, Dentistry, Gynecology and Pediatrics, Section of Pediatrics, Section of Pediatric Diabetes and Metabolism, University of Verona, Verona, Italy; Other Surgery, Dentistry, Gynecology and Pediatrics, Section of Health Care AG, Zürich, Switzerland; 13Department of Pediatrics, Korea University College of Medicine, Seoul, Korea; 14IPS University College of Medicine, Seoul, College of Medicine, Seoul, Korea; 14IPS University College of Medicine, Seoul, College of Medicine, Seo with ClinicalTrials.gov (NCT05013359). The authors acknowledge the medical writing assistance of Lauren McNally of Axis, a division of Spirit Medical Communications Group Limited. Presented at the European Society for Paediatric Endocrinology (ESPE) online conference, 22–26 September 2021